US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scinai Immunotherapeutics Ltd.

2.78

+0.01000.36%

Post-market: 2.780.00000.00%17:03 EDT

Volume:8.06K

Turnover:22.40K

Market Cap:2.60M

PE:0.34

High:2.88

Open:2.73

Low:2.73

Close:2.77

Loading ...

Overview Company News Filings

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Scinai Immunotherapeutics Signs Option Deal to Acquire Italy's Pincell

MT Newswires Live

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

Press Release: SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Press Release: Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability

Simply Wall St.

Press Release: Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Immunotherapeutics Reports Financial Turnaround and Growth

Scinai Immunotherapeutics Gains Shareholder Confidence

Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Press Release: Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SCNI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCNI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCNI\",,,,,undefined,":{"symbol":"SCNI","market":"US","secType":"STK","nameCN":"Scinai Immunotherapeutics Ltd.","latestPrice":2.78,"timestamp":1746216000000,"preClose":2.77,"halted":0,"volume":8055,"hourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.78,"latestTime":"17:03 EDT","volume":1,"amount":2.88,"timestamp":1746219785046},"delay":0,"floatShares":659200,"shares":933679,"eps":8.202362,"marketStatus":"Market Closed","change":0.01,"latestTime":"05-02 16:00:00 EDT","open":2.73,"high":2.88,"low":2.73,"amount":22397.460741,"amplitude":0.054152,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.202362,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"adrRate":4000,"listingDate":1431403200000,"exchange":"NASDAQ","adjPreClose":2.77,"preHourTrading":{"tag":"盘前","latestPrice":2.7012,"preClose":2.89,"latestTime":"09:00 EDT","volume":320,"amount":864.330048,"timestamp":1746190821868},"postHourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.78,"latestTime":"17:03 EDT","volume":1,"amount":2.88,"timestamp":1746219785046},"volumeRatio":0.215993},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCNI\",,,,,undefined,":{"symbol":"SCNI","floatShares":659200,"roa":"-33.22%","roe":"128.46%","lyrEps":-16.638636,"volumeRatio":0.215993,"shares":933679,"dividePrice":0,"high":2.88,"amplitude":0.054152,"preClose":2.77,"low":2.73,"week52Low":1.9,"pbRate":"0.26","psRate":"5.74","week52High":8.92,"institutionHeld":0,"latestPrice":2.78,"eps":8.202362,"divideRate":0,"volume":8055,"delay":0,"ttmEps":8.202362,"open":2.73,"prevYearClose":3.345,"prevWeekClose":2.5135,"prevMonthClose":2.6384,"prevQuarterClose":2.6939,"fiveDayClose":2.5135,"twentyDayClose":2.71,"sixtyDayClose":3.5747},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SCNI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532097071","title":"Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2532097071","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532097071?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape forPemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis .JERUSALEM, Israel, May 1, 2025 /PRNewswire/ --Scinai Immunotherapeutics Ltd. , a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and which provides CDMO services through its Scinai Bioservices unit, today announced that it will be hosting a webinar on Wednesday May 7th at, at 11:30 AM EST / 18:30 Israel time. The webinar will address the unmet needs in treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis  and explore Pincell's PC111, a novel monoclonal antibody targeting soluble Fas ligand  as a promising solution.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/scinai-immunotherapeutics-pincell-host-webinar-110000506.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scinai-immunotherapeutics-pincell-host-webinar-110000506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TEN","BK4077","BK4218","BK4007","BK4124","FENG","BK4144","BK4585","BK4588","BK4181","HST","SCNI","BK4139"],"gpt_icon":0},{"id":"2522008623","title":"Scinai Immunotherapeutics Signs Option Deal to Acquire Italy's Pincell","url":"https://stock-news.laohu8.com/highlight/detail?id=2522008623","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522008623?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:43","pubTimestamp":1743086632,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics  said Thursday it signed a binding option agreement to acquire Italian biotech firm Pincell by the end of the year.Pincell's PC111 product candidate is under development for the treatment of Pemphigus, Steven Johnson's Syndrome, and Toxic Epidermal Necrolysis. Scinai said PC111 has the potential for accelerated approval given the severity of these diseases and its non-immunosuppressive mechanism of action.To facilitate a grant application, Pincell exclusively licensed PC111 to Scinai's wholly owned Polish subsidiary, which submitted an application under the European Funds for a Modern Economy program in Poland. Scinai is seeking 12 million euros  in non-dilutive funding for PC111's development.If Scinai exercises the option to acquire Pincell, the Italian company's shareholders will be eligible for milestone payments and royalties on future net sales of PC111 in the low single digits.The financial terms of the option agreement were not disclosed.Shares of Scin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCNI","BK4007","BK4139"],"gpt_icon":0},{"id":"2522304467","title":"Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304467","media":"PR Newswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304467?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:25","pubTimestamp":1743081900,"startTime":"0","endTime":"0","summary":"Scinai files an application for Euro 12 million grant to fund next stage of development. Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome  and Toxic Epidermal Necrolysis . PC111 has already received an Orphan Drug Designation inPemphigus by the European Medicine's Agency. An application will be filed with the FDA for Orphan Drug and Breakthrough Designation inPemphigus, as well as in SJS/TEN. Scinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatments. Pincell has carried out a large number of in-vitro, ex-vivo and in-vivo experiments using PC111 without steroids in validated models of pemphigus, to prove that soluble FasL is a critical target in this disease. Most importantly, Pincell has demonstrated that PC111 can block blister formation without steroids in a transgenic humanized FasL mouse model o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/scinai-signs-option-agreement-acquire-132500392.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scinai-signs-option-agreement-acquire-132500392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","TEN","BK4124","BK4077","BK4139","SCNI","FENG","BK4007"],"gpt_icon":0},{"id":"2517916196","title":"Scinai Immunotherapeutics announces $10M standby equity purchase agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517916196?lang=en_us&edition=fundamental","pubTime":"2025-03-05 20:37","pubTimestamp":1741178256,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) announced that it has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., a fund managed by York...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-announces-10m-standby-equity-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scinai-immunotherapeutics-announces-10m-standby-equity-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCNI","BK4139","BK4007"],"gpt_icon":0},{"id":"2517916988","title":"Press Release: SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916988","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517916988?lang=en_us&edition=fundamental","pubTime":"2025-03-05 20:30","pubTimestamp":1741177800,"startTime":"0","endTime":"0","summary":"JERUSALEM, March 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that it has entered into a Standby Equity Purchase Agreement  with YA II PN, Ltd. , a fund managed by Yorkville Advisors Global, LP.Under the terms of the SEPA, Scinai has the right, but not the obligation, to sell up to $10 million  of its American Depository Shares , each representing 4,000 ordinary shares, to Yorkville at any time during the three-year period following the execution date of the SEPA and following the effectiveness of a registration statement filed with the Securities and Exchange Commission registering the ordinary shares represented by the ADSs issuable pursuant to the SEPA. Sales to Yorkville under the SEPA are subject to a beneficial ownership cap of 9.99% of Scinai's share capital at any one time, along ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4215","BK4007","SCNI","EQR","BK4588"],"gpt_icon":0},{"id":"2501236166","title":"Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2501236166","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501236166?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:30","pubTimestamp":1736166600,"startTime":"0","endTime":"0","summary":"JERUSALEM, Jan. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today that its CEO, Mr. Amir Reichman, and Chairman of the Board, Mr. Mark Germain, will attend the IATI Mini Mixiii Conference in Miami, FL on Jan 9, 2025 and the JP Morgan HealthCare Conference week in San Francisco from Jan 13-15, 2025. On Jan 14, 2025, Mr. Reichman and Mr. Germain will also participate in the SIC Biotech Symposium in San Francisco.Institutional and private investors interested in Scinai's value proposition.Potential pharma partners in the inflammation & immunology field interested in co-developing or in-licensing Scinai's innovative NanoAbs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/scinai-connect-investors-pharma-leaders-123000041.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scinai-connect-investors-pharma-leaders-123000041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SCNI","ISBC","BK4007","BK4211"],"gpt_icon":0},{"id":"2491405618","title":"Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2491405618","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491405618?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:25","pubTimestamp":1734359100,"startTime":"0","endTime":"0","summary":"JERUSALEM, Dec. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today the establishment of a U.S.-based subsidiary for its Contract Development and Manufacturing Services. The new subsidiary, incorporated in Delaware, will operate under the name Scinai Bioservices Inc.In 2024, Scinai launched its CDMO business unit, branded as Scinai Bioservices, operating from the Company's site in Jerusalem, Israel. This facility includes 1,850 square meters  of clean rooms and laboratories, all operating under cGMP conditions in compliance with European Medicines Agency  and FDA requirements.Scinai's new U.S. subsidiary, Scinai Bioservices Inc., aims to serve U.S.-based early-stage biotech companies by providing the required CDMO services that are currently in short supply. This is coupled with growing d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NwNW45kpBFBmBXlHa8cj0A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8865f453b326692174ace4c4e2150008","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NwNW45kpBFBmBXlHa8cj0A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8865f453b326692174ace4c4e2150008"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/scinai-immunotherapeutics-establishes-u-subsidiary-142500378.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scinai-immunotherapeutics-establishes-u-subsidiary-142500378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","SCNI","CDMO"],"gpt_icon":0},{"id":"2489459688","title":"Press Release: Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2489459688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489459688?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:25","pubTimestamp":1733405100,"startTime":"0","endTime":"0","summary":"Prof. Michael Schn, Director of Dermatology and Venereology at the University Medical Center Gttingen, Germany , Joins Scinai Immunotherapeutics' Scientific Advisory Board. JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today the appointment of Prof. Michael Schn to its Scientific Advisory Board .Amir Reichman, CEO of Scinai, stated: \"We are thrilled to welcome Prof. Schn, a world-class expert in dermatology, particularly in psoriasis and atopic dermatitis, to our Scientific Advisory Board. Michael's extensive experience as a dermatologist, having treated thousands of patients, and as a researcher with over 440 scientific publications in top-rated journals, along with his proven track record in drug development and clinical research, will be invaluable to Scinai. His insi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDF","SCNI","BK4007"],"gpt_icon":0},{"id":"2487370405","title":"There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2487370405","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487370405?lang=en_us&edition=fundamental","pubTime":"2024-11-29 19:04","pubTimestamp":1732878290,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics Ltd.'s  stock performed strongly after the recent earnings report. However, we think that investors should be cautious when interpreting the profit numbers.Check out our latest analysis for Scinai Immunotherapeutics. NasdaqCM:SCNI Earnings and Revenue History November 29th 2024. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. To quote a 2014 paper by Lewellen and Resutek, \"firms with higher accruals tend to be less profitable in the future\".A Look At The Impact Of Scinai Immunotherapeutics' Dilution On Its Earnings Per Share . Scinai Immunotherapeutics was losing money three years ago. And even focusing only on the last twelve months, we don't have a meaningful growth rate because it made a loss a year ago, too. What we do know ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/reasons-suggest-scinai-immunotherapeutics-nasdaq-110450880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SCNI","NDAQ",".IXIC"],"gpt_icon":0},{"id":"2486829325","title":"Press Release: Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2486829325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486829325?lang=en_us&edition=fundamental","pubTime":"2024-11-27 21:00","pubTimestamp":1732712400,"startTime":"0","endTime":"0","summary":"Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board. JERUSALEM, Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today that Dr. Jonathan Sadeh has been appointed as a member of the Company's Scientific Advisory Board . In this capacity, Dr Sadeh will play a significant role in advancing the clinical development of Scinai's lead IL-17 program along with other promising assets in their unique VHH antibody pipeline.Amir Reichman, CEO of Scinai, commented: \"We are thrilled to welcome Dr. Jonathan Sadeh to our Scientific Advisory Board. His extensive experience and proven track record in drug development and clinical research will be invaluable as we continue to advance our pipelin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","BK4139","BMS","BK4007","SCNI"],"gpt_icon":0},{"id":"2486033937","title":"Scinai Immunotherapeutics Reports Financial Turnaround and Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2486033937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486033937?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:54","pubTimestamp":1732546448,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics has successfully turned around its financial standing by convert...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scinai-immunotherapeutics-reports-financial-turnaround-and-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scinai-immunotherapeutics-reports-financial-turnaround-and-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SCNI","BK4139"],"gpt_icon":0},{"id":"2485265644","title":"Scinai Immunotherapeutics Gains Shareholder Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2485265644","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485265644?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:57","pubTimestamp":1732283843,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd has successfully held its Annual Meeting of Shareholders, se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scinai-immunotherapeutics-gains-shareholder-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scinai-immunotherapeutics-gains-shareholder-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCNI","BK4007","BK4139"],"gpt_icon":0},{"id":"2485025410","title":"Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K","url":"https://stock-news.laohu8.com/highlight/detail?id=2485025410","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485025410?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:27","pubTimestamp":1732278470,"startTime":"0","endTime":"0","summary":"Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42135437/scinai-immunotherapeutics-q3-eps-0-0021-up-from-0-002-yoy-sales-168k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNI"],"gpt_icon":0},{"id":"2485251741","title":"Press Release: Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2485251741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485251741?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:15","pubTimestamp":1732277700,"startTime":"0","endTime":"0","summary":"Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million. JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  , a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update.Conversion of EIB Loan into Equity bringing shareholders' equity to $10 million. Following the conversion, the total outstanding amount owed by the Company to the EIB was reduced to EUR 250,000 . This remaining outstanding amount has a maturity date of December 31, 2031, is not prepayable in advance, and no interest accrues or is due and payable on such amount.On August 29, 2024, the Company announced that on August 27, 2024, it had received formal notification fr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EQR","BK4588","BK4139","BK4585","SCNI","BK4215"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCNI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-21","symbol":"SCNI","defaultRemindTime":1716298200000,"type":"split","dateTimestamp":1716264000000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCNI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCNI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCNI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCNI","date":"2025-05-01","current":0.524578,"percent":0.782946,"low":-2.685473,"twenty":-0.575134,"median":-0.2437,"eighty":0.594336,"high":0.712948,"avg":-0.151527,"sd":0.512865,"marketCap":2463418},"quantilePoints":[{"date":"2023-09-15","current":-0.556301,"twenty":-0.631114,"median":-0.628237,"eighty":-0.610051,"marketCap":4236234},{"date":"2023-09-22","current":-0.494851,"twenty":-0.629196,"median":-0.556301,"eighty":-0.484902,"marketCap":3768291},{"date":"2023-09-29","current":-0.462925,"twenty":-0.625388,"median":-0.490861,"eighty":-0.469979,"marketCap":3525175},{"date":"2023-10-06","current":-0.372469,"twenty":-0.583176,"median":-0.478888,"eighty":-0.458668,"marketCap":2836348},{"date":"2023-10-13","current":-0.345864,"twenty":-0.541747,"median":-0.469112,"eighty":-0.399372,"marketCap":2633751},{"date":"2023-10-20","current":-0.402851,"twenty":-0.509729,"median":-0.462925,"eighty":-0.399052,"marketCap":3067713},{"date":"2023-10-27","current":-0.345864,"twenty":-0.494851,"median":-0.452283,"eighty":-0.398967,"marketCap":2633751},{"date":"2023-11-03","current":-0.305443,"twenty":-0.48687,"median":-0.415808,"eighty":-0.351185,"marketCap":2836348},{"date":"2023-11-10","current":-0.307765,"twenty":-0.47942,"median":-0.402851,"eighty":-0.329954,"marketCap":2857909},{"date":"2023-11-17","current":-0.290566,"twenty":-0.478888,"median":-0.399046,"eighty":-0.304625,"marketCap":2698194},{"date":"2023-11-24","current":-0.280724,"twenty":-0.471761,"median":-0.396359,"eighty":-0.296716,"marketCap":2606803},{"date":"2023-12-01","current":-0.336963,"twenty":-0.469979,"median":-0.372469,"eighty":-0.295253,"marketCap":3129034},{"date":"2023-12-08","current":-0.345586,"twenty":-0.468593,"median":-0.345936,"eighty":-0.296423,"marketCap":3209110},{"date":"2023-12-15","current":-0.356177,"twenty":-0.463989,"median":-0.345864,"eighty":-0.296716,"marketCap":3307463},{"date":"2023-12-22","current":-0.323372,"twenty":-0.462925,"median":-0.342844,"eighty":-0.300207,"marketCap":3002828},{"date":"2023-12-29","current":-0.328011,"twenty":-0.458668,"median":-0.338946,"eighty":-0.298462,"marketCap":3045913},{"date":"2024-01-05","current":-0.288691,"twenty":-0.452283,"median":-0.33762,"eighty":-0.295721,"marketCap":2680786},{"date":"2024-01-12","current":-0.269476,"twenty":-0.425678,"median":-0.329954,"eighty":-0.292353,"marketCap":2502357},{"date":"2024-01-19","current":-0.248387,"twenty":-0.424827,"median":-0.328058,"eighty":-0.28754,"marketCap":2306520},{"date":"2024-01-26","current":-0.2437,"twenty":-0.410524,"median":-0.328058,"eighty":-0.280724,"marketCap":2263001},{"date":"2024-02-02","current":-0.220736,"twenty":-0.404873,"median":-0.328011,"eighty":-0.276506,"marketCap":2049757},{"date":"2024-02-09","current":-0.234327,"twenty":-0.403149,"median":-0.31824,"eighty":-0.271351,"marketCap":2175963},{"date":"2024-02-16","current":-0.239014,"twenty":-0.400255,"median":-0.308843,"eighty":-0.261509,"marketCap":2219482},{"date":"2024-02-23","current":-0.234327,"twenty":-0.399286,"median":-0.305443,"eighty":-0.25163,"marketCap":2175963},{"date":"2024-03-01","current":-0.230062,"twenty":-0.399041,"median":-0.302852,"eighty":-0.241826,"marketCap":2136360},{"date":"2024-03-08","current":-0.234327,"twenty":-0.398988,"median":-0.296716,"eighty":-0.234778,"marketCap":2175963},{"date":"2024-03-15","current":-0.234327,"twenty":-0.395838,"median":-0.295253,"eighty":-0.234749,"marketCap":2175963},{"date":"2024-03-22","current":-0.2437,"twenty":-0.381301,"median":-0.292353,"eighty":-0.234327,"marketCap":2263001},{"date":"2024-03-28","current":-0.234327,"twenty":-0.372788,"median":-0.288691,"eighty":-0.234327,"marketCap":2175963},{"date":"2024-04-05","current":-0.220314,"twenty":-0.365952,"median":-0.283466,"eighty":-0.234327,"marketCap":2045840},{"date":"2024-04-12","current":-0.224954,"twenty":-0.35418,"median":-0.280724,"eighty":-0.232875,"marketCap":2088924},{"date":"2024-04-19","current":-0.213706,"twenty":-0.349114,"median":-0.278998,"eighty":-0.229809,"marketCap":1984478},{"date":"2024-04-26","current":-0.210894,"twenty":-0.34595,"median":-0.276506,"eighty":-0.228872,"marketCap":1958366},{"date":"2024-05-03","current":-0.215839,"twenty":-0.345864,"median":-0.27182,"eighty":-0.22621,"marketCap":2004279},{"date":"2024-05-10","current":-0.202037,"twenty":-0.345753,"median":-0.267227,"eighty":-0.225554,"marketCap":1876115},{"date":"2024-05-17","current":-0.210894,"twenty":-0.34478,"median":-0.260103,"eighty":-0.224954,"marketCap":1958366},{"date":"2024-05-24","current":-0.246473,"twenty":-0.34478,"median":-0.25776,"eighty":-0.224954,"marketCap":1602072},{"date":"2024-05-31","current":-0.241029,"twenty":-0.34328,"median":-0.25776,"eighty":-0.224982,"marketCap":1566691},{"date":"2024-06-07","current":-0.27778,"twenty":-0.341484,"median":-0.253412,"eighty":-0.225161,"marketCap":1805568},{"date":"2024-06-14","current":-0.201431,"twenty":-0.338946,"median":-0.252049,"eighty":-0.224954,"marketCap":1309303},{"date":"2024-06-21","current":-0.280004,"twenty":-0.33958,"median":-0.253049,"eighty":-0.224954,"marketCap":1820024},{"date":"2024-06-28","current":-0.204288,"twenty":-0.338719,"median":-0.252049,"eighty":-0.224954,"marketCap":1327875},{"date":"2024-07-05","current":-0.282059,"twenty":-0.337809,"median":-0.253049,"eighty":-0.224954,"marketCap":1450912},{"date":"2024-07-12","current":-0.310491,"twenty":-0.337431,"median":-0.25776,"eighty":-0.224954,"marketCap":1597164},{"date":"2024-07-15","current":-0.366451,"twenty":-0.337733,"median":-0.258765,"eighty":-0.224954,"marketCap":1885025},{"date":"2024-08-02","current":-0.375477,"twenty":-0.338491,"median":-0.259769,"eighty":-0.224954,"marketCap":1931454},{"date":"2024-08-09","current":-0.330348,"twenty":-0.338491,"median":-0.264459,"eighty":-0.224954,"marketCap":1699308},{"date":"2024-08-16","current":-0.85352,"twenty":-0.345753,"median":-0.267227,"eighty":-0.22501,"marketCap":3161439},{"date":"2024-08-23","current":-0.907856,"twenty":-0.350432,"median":-0.271786,"eighty":-0.225226,"marketCap":3362697},{"date":"2024-08-30","current":-0.88748,"twenty":-0.372788,"median":-0.276506,"eighty":-0.225554,"marketCap":3287225},{"date":"2024-09-06","current":-0.803984,"twenty":-0.397924,"median":-0.276506,"eighty":-0.225779,"marketCap":2977958},{"date":"2024-09-13","current":-0.760697,"twenty":-0.399925,"median":-0.277482,"eighty":-0.225891,"marketCap":2817622},{"date":"2024-09-20","current":-0.817296,"twenty":-0.421092,"median":-0.279263,"eighty":-0.225947,"marketCap":3027266},{"date":"2024-09-27","current":-0.937287,"twenty":-0.462925,"median":-0.280724,"eighty":-0.226192,"marketCap":3471712},{"date":"2024-10-04","current":-0.839936,"twenty":-0.477106,"median":-0.281193,"eighty":-0.226275,"marketCap":3111124},{"date":"2024-10-11","current":-0.844464,"twenty":-0.524606,"median":-0.283639,"eighty":-0.226341,"marketCap":3127895},{"date":"2024-10-18","current":-0.821825,"twenty":-0.611001,"median":-0.28799,"eighty":-0.226838,"marketCap":3044038},{"date":"2024-10-25","current":-0.787865,"twenty":-0.630155,"median":-0.291459,"eighty":-0.228623,"marketCap":2918251},{"date":"2024-10-31","current":-0.805977,"twenty":-0.760697,"median":-0.295252,"eighty":-0.229617,"marketCap":2985337},{"date":"2024-11-08","current":-0.792393,"twenty":-0.772017,"median":-0.295721,"eighty":-0.229641,"marketCap":2935023},{"date":"2024-11-15","current":-0.674666,"twenty":-0.772017,"median":-0.298898,"eighty":-0.229641,"marketCap":2498962},{"date":"2024-11-22","current":-0.683722,"twenty":-0.769753,"median":-0.304625,"eighty":-0.229641,"marketCap":2532505},{"date":"2024-11-29","current":0.624851,"twenty":-0.762508,"median":-0.30108,"eighty":-0.229369,"marketCap":2934302},{"date":"2024-12-06","current":0.592156,"twenty":-0.760697,"median":-0.296218,"eighty":-0.226247,"marketCap":2780763},{"date":"2024-12-13","current":0.612136,"twenty":-0.760697,"median":-0.295252,"eighty":-0.225685,"marketCap":2874593},{"date":"2024-12-20","current":0.612136,"twenty":-0.755263,"median":-0.291459,"eighty":-0.224954,"marketCap":2874593},{"date":"2024-12-27","current":0.624851,"twenty":-0.72402,"median":-0.28834,"eighty":-0.224654,"marketCap":2934302},{"date":"2025-01-03","current":0.624851,"twenty":-0.699569,"median":-0.285479,"eighty":-0.22188,"marketCap":2934302},{"date":"2025-01-10","current":0.628484,"twenty":-0.690967,"median":-0.282059,"eighty":-0.220352,"marketCap":2951362},{"date":"2025-01-17","current":0.647557,"twenty":-0.682816,"median":-0.281146,"eighty":-0.220268,"marketCap":3040927},{"date":"2025-01-24","current":0.643379,"twenty":-0.679194,"median":-0.280724,"eighty":-0.215839,"marketCap":3021308},{"date":"2025-01-31","current":0.639383,"twenty":-0.674666,"median":-0.278998,"eighty":-0.213285,"marketCap":3002542},{"date":"2025-02-07","current":0.712948,"twenty":-0.663346,"median":-0.277184,"eighty":-0.210894,"marketCap":3348005},{"date":"2025-02-14","current":0.588523,"twenty":-0.645234,"median":-0.276506,"eighty":-0.20991,"marketCap":2763703},{"date":"2025-02-21","current":0.613154,"twenty":-0.637989,"median":-0.274163,"eighty":-0.20617,"marketCap":2879369},{"date":"2025-02-28","current":0.642398,"twenty":-0.633661,"median":-0.271752,"eighty":-0.203838,"marketCap":3016702},{"date":"2025-03-07","current":0.62031,"twenty":-0.631114,"median":-0.26718,"eighty":-0.192145,"marketCap":2912977},{"date":"2025-03-14","current":0.604871,"twenty":-0.628717,"median":-0.263556,"eighty":0.592156,"marketCap":2840473},{"date":"2025-03-21","current":0.617586,"twenty":-0.624439,"median":-0.258765,"eighty":0.599421,"marketCap":2900183},{"date":"2025-03-28","current":0.526782,"twenty":-0.622773,"median":-0.253073,"eighty":0.601427,"marketCap":2473770},{"date":"2025-04-04","current":0.492252,"twenty":-0.614884,"median":-0.251069,"eighty":0.599756,"marketCap":2311616},{"date":"2025-04-11","current":0.399705,"twenty":-0.612957,"median":-0.249289,"eighty":0.599425,"marketCap":1877015},{"date":"2025-04-17","current":0.348754,"twenty":-0.607088,"median":-0.246473,"eighty":0.599421,"marketCap":1637750},{"date":"2025-04-25","current":0.439576,"twenty":-0.593884,"median":-0.243934,"eighty":0.597242,"marketCap":2064247},{"date":"2025-05-01","current":0.524578,"twenty":-0.575134,"median":-0.2437,"eighty":0.594336,"marketCap":2463418}],"updateTime":1746239133021}}}